Albemarle Corporation publishes investor presentation outlining strategy and FY 2025 net sales of USD 5.1 billion

Reuters
Mar 19
Albemarle Corporation publishes investor presentation outlining strategy and FY 2025 net sales of USD 5.1 billion

Albemarle reported FY 2025 net sales of USD 5.1 billion and an adjusted EBITDA margin of about 21%. The company said FY 2025 free cash flow was USD 692 million and operating cash flow conversion was 117%. Albemarle said it delivered about USD 450 million in cost and productivity improvements and is targeting USD 100-150 million of additional improvements in FY 2026E. The company said it reduced FY 2025 capex to USD 590 million and is targeting FY 2026E capex of USD 550-600 million. Albemarle reported cash and cash equivalents of USD 1.62 billion and total liquidity of USD 3.2 billion.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Albemarle Corporation published the original content used to generate this news brief on March 18, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10